BiotechTube

Doxycycline Hyclate Delayed-Release 200 mg

ApprovedCompleted
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Gonorrhea

Conditions

Gonorrhea, Chlamydia, Syphilis

Trial Timeline

Nov 26, 2019 → Jun 12, 2023

NCT ID
NCT03980223

About Doxycycline Hyclate Delayed-Release 200 mg

Doxycycline Hyclate Delayed-Release 200 mg is a approved stage product being developed by Mayne Pharma Group for Gonorrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT03980223. Target conditions include Gonorrhea, Chlamydia, Syphilis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03980223ApprovedCompleted

Competing Products

2 competing products in Gonorrhea

See all competitors
ProductCompanyStageHype Score
Trumenba Vaccine + MenACWY VaccinePfizerPre-clinical
22
solithromycin + ceftriaxone + azithromycinAllergy TherapeuticsPhase 3
72

Other Products from Mayne Pharma Group

Sporanox + LozanocApproved
77
Halobetasol Topical FoamApproved
77
Slow release oral morphine (SROM) + MethadonePhase 3
69
Permethrin Cream, 5% + ElimitePhase 3
69
Ivermectin 0.5% Topical Application Lotion + Ivermectin 0.5% Topical Application Lotion [SKLICE] + Placebo 0% LotionPhase 3
69